KR20260036611A - 골수증식성 신생물 및 암과 연관된 섬유증의 치료를 위한 pim 키나제 억제제 - Google Patents

골수증식성 신생물 및 암과 연관된 섬유증의 치료를 위한 pim 키나제 억제제

Info

Publication number
KR20260036611A
KR20260036611A KR1020267006173A KR20267006173A KR20260036611A KR 20260036611 A KR20260036611 A KR 20260036611A KR 1020267006173 A KR1020267006173 A KR 1020267006173A KR 20267006173 A KR20267006173 A KR 20267006173A KR 20260036611 A KR20260036611 A KR 20260036611A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267006173A
Other languages
English (en)
Korean (ko)
Inventor
제이슨 마크 폴크스
스티븐 엘. 워너
Original Assignee
스미토모 파마 아메리카, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스미토모 파마 아메리카, 인크. filed Critical 스미토모 파마 아메리카, 인크.
Publication of KR20260036611A publication Critical patent/KR20260036611A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020267006173A 2018-04-13 2019-04-12 골수증식성 신생물 및 암과 연관된 섬유증의 치료를 위한 pim 키나제 억제제 Pending KR20260036611A (ko)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201862657540P 2018-04-13 2018-04-13
US201862657563P 2018-04-13 2018-04-13
US62/657,540 2018-04-13
US62/657,563 2018-04-13
US201862743469P 2018-10-09 2018-10-09
US62/743,469 2018-10-09
US201862753025P 2018-10-30 2018-10-30
US201862753023P 2018-10-30 2018-10-30
US62/753,023 2018-10-30
US62/753,025 2018-10-30
PCT/US2019/027217 WO2019200254A1 (en) 2018-04-13 2019-04-12 Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
KR1020207032677A KR20200143454A (ko) 2018-04-13 2019-04-12 골수증식성 신생물 및 암과 연관된 섬유증의 치료를 위한 pim 키나제 억제제

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207032677A Division KR20200143454A (ko) 2018-04-13 2019-04-12 골수증식성 신생물 및 암과 연관된 섬유증의 치료를 위한 pim 키나제 억제제

Publications (1)

Publication Number Publication Date
KR20260036611A true KR20260036611A (ko) 2026-03-17

Family

ID=68164545

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020267006173A Pending KR20260036611A (ko) 2018-04-13 2019-04-12 골수증식성 신생물 및 암과 연관된 섬유증의 치료를 위한 pim 키나제 억제제
KR1020207032677A Pending KR20200143454A (ko) 2018-04-13 2019-04-12 골수증식성 신생물 및 암과 연관된 섬유증의 치료를 위한 pim 키나제 억제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207032677A Pending KR20200143454A (ko) 2018-04-13 2019-04-12 골수증식성 신생물 및 암과 연관된 섬유증의 치료를 위한 pim 키나제 억제제

Country Status (9)

Country Link
US (2) US20210113562A1 (https=)
EP (1) EP3773560A4 (https=)
JP (2) JP2021521170A (https=)
KR (2) KR20260036611A (https=)
CN (3) CN117838695A (https=)
AU (2) AU2019252793A1 (https=)
CA (1) CA3095580A1 (https=)
MX (2) MX2020010556A (https=)
WO (1) WO2019200254A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
EP4611753A1 (en) * 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP1257546A1 (en) 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
MXPA06003054A (es) 2003-09-18 2006-05-31 Novartis Ag 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos.
CN101321760A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
BRPI0718029A2 (pt) 2006-11-06 2013-11-26 Supergen Inc Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
US8846704B2 (en) 2007-01-31 2014-09-30 YM Biosciences Austraila Pty Ltd Thiopyrimidine-based compounds and uses thereof
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
MX2009009117A (es) 2007-03-01 2009-09-03 Supergen Inc Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
WO2008118823A2 (en) 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
IL295053A (en) 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
EP2139869A2 (en) 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
EP2217235A4 (en) 2007-11-15 2011-01-12 Musc Found For Res Dev INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
NZ586662A (en) 2007-12-19 2012-08-31 Vertex Pharma PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS
EP2234986A2 (en) 2007-12-20 2010-10-06 Cellzome Limited Sulfamides as zap-70 inhibitors
AR070531A1 (es) 2008-03-03 2010-04-14 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
FR2933409B1 (fr) 2008-07-03 2010-08-27 Centre Nat Rech Scient NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
MX2011001426A (es) 2008-08-05 2011-03-21 Targegen Inc Metodos para tratar la talasemia.
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
AU2009289317A1 (en) 2008-09-02 2010-03-11 Novartis Ag Heterocyclic PIM-kinase inhibitors
WO2010026121A1 (en) 2008-09-02 2010-03-11 Novartis Ag Bicyclic kinase inhibitors
MX2011002365A (es) 2008-09-02 2011-04-04 Novartis Ag Derivados de picolinamida como inhibidres de cinasa.
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
AU2010236389A1 (en) 2009-04-15 2011-11-24 Nationwide Children's Hospital, Inc. Curcumin analogs as dual JAK2/STAT3 inhibitors and methods of making and using the same
BRPI1011066A2 (pt) 2009-05-20 2017-03-21 Cylene Pharmaceuticals Inc "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
US20100331315A1 (en) 2009-06-18 2010-12-30 Mustapha Haddach Rhodanines and related heterocycles as kinase inhibitors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EP2332917B1 (en) 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Compounds for PIM kinase inhibition and for treating malignancy
EP2515665B1 (en) 2009-12-22 2013-08-14 Unilever NV A process for preparing a tea product
PL2516425T3 (pl) 2009-12-23 2016-03-31 Jasco Pharmaceuticals Llc Inhibitory kinaz aminopirydynowych
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
JP2013530199A (ja) 2010-07-06 2013-07-25 ノバルティス アーゲー キナーゼ阻害剤として有用な環状エーテル化合物
EP2614065B1 (en) 2010-12-17 2017-04-19 Nerviano Medical Sciences S.r.l. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
PL2678329T3 (pl) 2011-02-25 2016-06-30 Array Biopharma Inc Związki triazolopirydyny jako inhibitory kinaz pim
WO2012120415A1 (en) 2011-03-04 2012-09-13 Novartis Ag Tetrasubstituted cyclohexyl compounds as kinase inhibitors
EP2688886A1 (en) 2011-03-22 2014-01-29 Amgen Inc. Azole compounds as pim inhibitors
ES2595407T3 (es) * 2011-06-14 2016-12-29 Novartis Ag Combinación de panobinostat y ruxolitinib en el tratamiento de cáncer, tal como una neoplasia mieloproliferativa
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP2734205B1 (en) * 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
CN102924445B (zh) 2011-08-11 2015-07-08 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
WO2013059738A2 (en) 2011-10-19 2013-04-25 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2013173518A1 (en) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US9173883B2 (en) 2012-05-21 2015-11-03 Novartis Ag Ring-substituted N-pyridinyl amides as kinase inhibitors
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
BR112015002709B1 (pt) 2012-08-06 2022-09-20 Acea Biosciences Inc Compostos, composição farmacêutica, uso dos mesmos e uso de uma combinação de composto ou composição farmacêutica e um segundo agente profilático ou agente terapêutico
KR101446742B1 (ko) 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN102880459A (zh) 2012-08-14 2013-01-16 张涛 基于VisualLisp编程语言下的编译实现方法及系统
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
CN104812756A (zh) 2012-09-26 2015-07-29 曼凯德公司 多激酶通路抑制剂
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
AU2014214846A1 (en) 2013-02-08 2015-07-23 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US10322125B2 (en) 2013-02-22 2019-06-18 Emory University TGF-beta enhancing compositions for cartilage repair and methods related thereto
WO2014130693A1 (en) 2013-02-25 2014-08-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
JP2016512549A (ja) 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
HK1215374A1 (zh) 2013-04-08 2016-08-26 Pharmacyclics Llc 依鲁替尼联合疗法
KR102094011B1 (ko) 2013-06-13 2020-03-26 삼성전자주식회사 전자 장치에서 노이즈를 제거하기 위한 장치 및 방법
JP6458018B2 (ja) 2013-07-02 2019-01-23 ファーマサイクリックス エルエルシー キナーゼ阻害剤としてのプリノン化合物
JP2016527305A (ja) * 2013-08-08 2016-09-08 ノバルティス アーゲー Ｐｉｍキナーゼ阻害剤の組合せ
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
CA2925124A1 (en) 2013-09-30 2015-04-02 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
AU2014354821A1 (en) * 2013-11-27 2016-05-26 Novartis Ag Combination therapy comprising an inhibitor of JAK, CDK and PIM
EP3102238A1 (en) * 2014-01-20 2016-12-14 Gilead Sciences, Inc. Therapies for treating cancers
PH12020552277A1 (en) 2014-04-08 2023-07-17 Incyte Holdings Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
US20150306112A1 (en) 2014-04-25 2015-10-29 National Cheng Kung University Zhankuic acid A, a JAK2/3 tyrosine kinase inhibitor, and a potential therapeutic agent for hepatitis
WO2016161248A1 (en) 2015-04-02 2016-10-06 Tolero Pharmaceuticals, Inc. Targeting pim kinases in combination with btk inhibition
CN105919955A (zh) * 2016-06-13 2016-09-07 佛山市腾瑞医药科技有限公司 一种鲁索利替尼制剂及其应用
WO2020146440A1 (en) * 2019-01-09 2020-07-16 Celgene Corporation Antiproliferative compounds and second active agents for use in treating multiple myeloma
NZ778055A (en) * 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
WO2021080955A1 (en) * 2019-10-21 2021-04-29 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use

Also Published As

Publication number Publication date
KR20200143454A (ko) 2020-12-23
EP3773560A4 (en) 2022-01-19
CA3095580A1 (en) 2019-10-17
US20210113562A1 (en) 2021-04-22
JP2021521170A (ja) 2021-08-26
JP2024038485A (ja) 2024-03-19
CN117959303A (zh) 2024-05-03
CN112236139A (zh) 2021-01-15
AU2019252793A1 (en) 2020-10-15
MX2023001425A (es) 2023-03-03
AU2025201505A1 (en) 2025-03-20
MX2020010556A (es) 2021-03-02
CN117838695A (zh) 2024-04-09
EP3773560A1 (en) 2021-02-17
US20250082634A1 (en) 2025-03-13
WO2019200254A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
JP6838085B2 (ja) Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
US20250082634A1 (en) Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
TWI631950B (zh) 藉二氫吡𠯤并吡𠯤治療癌症
Gora-Tybor et al. Targeted drugs in chronic myeloid leukemia
TWI656875B (zh) 藉二氫吡并吡治療癌症
TWI674897B (zh) 藉二氫吡并吡化合物組合療法的癌症治療方法
TW201526894A (zh) 藉二氫吡并吡治療癌症
US9340532B2 (en) Methods and compositions for inhibiting CNKSR1
US20180110796A1 (en) Compositions and methods for the treatment of hbv infection
CN121311605A (zh) 通过kras突变来关联akr1c3酶表达水平及医药用途
US20090075972A1 (en) Use of Midostaurin for Treating Gastrointestinal Stromal Tumors
CN116940365A (zh) 慢性髓性白血病干细胞抑制剂
KR20190008315A (ko) 진행 단계 비소세포 폐암을 치료하기 위한 방법 및 조성물
NZ629860B (en) Methods for treating cancer using tor kinase inhibitor combination therapy

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)